retatrutide type 2 diabetes Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA How Does Retatrutide Work? Doctor

Diabetes 58 , 469477 (2009)

Biochem 25 , 623633 (2014)

Over 72 weeks, the 15 mg dose delivered a mean weight reduction of about 20.9%, and the 10 mg dose about 19.5%

For researchers studying metabolic mechanisms, this triple-agonist approach also opens up research avenues that semaglutide cannot, particularly around glucagon-mediated energy expenditure and hepatic fat metabolism

GLP1 Dose Calculator This tool was created to help you or your provider calculate the correct dose of GLP-1 medicationslike Mounjaro (tirzepatide)with ease and accuracy

It's typically mild tingling, altered sensation, especially in the limbs and dose-dependent